More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.43B
EPS
-5.41
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.775577
Previous close
$26.80
Today's open
$26.82
Day's range
$26.48 - $28.49
52 week range
$23.82 - $43.10
show more
CEO
Brian Lian
Employees
53
Headquarters
San Diego, CA
Exchange
NASDAQ Capital Market
Shares outstanding
127522189
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.
Viking Therapeutics has four phase 3 obesity trials underway for VK2735. Significant upside exists, but risks and competition remain high.
The Motley Fool • 6 hours ago

Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing
Viking Therapeutics NASDAQ: VKTX is preparing for a potential 2029 launch of its obesity drug candidate VK2735 while studying whether patients can maintain weight loss with less frequent injections or a daily oral tablet, CEO Brian Lian said at the Jefferies Global Healthcare Conference in London.
MarketBeat • 41 minutes ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 2 hours ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026, in Washington, D.C. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.
PRNewsWire • Nov 15, 2026

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Viking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share. Peak sales and valuation projections need to be based on risk-adjusted scenarios.
The Motley Fool • Nov 13, 2026

4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
Zacks Investment Research • Nov 13, 2026

Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.
FXEmpire • Nov 11, 2026

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company, is also looking to make waves in this market.
The Motley Fool • Nov 11, 2026

Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will present two posters highlighting its VK2735 program at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026, in Washington, D.C. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.
PRNewsWire • Nov 9, 2026

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
Zacks Investment Research • Nov 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Viking Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.